Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 571.2% in July

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 177,544 shares, an increase of 571.2% from the July 15th total of 26,452 shares. Based on an average daily volume of 466,302 shares, the short-interest ratio is presently 0.4 days. Approximately 1.2% of the shares of the stock are short sold.

Institutional Trading of Enlivex Therapeutics

A number of hedge funds have recently made changes to their positions in ENLV. Virtu Financial LLC purchased a new stake in Enlivex Therapeutics during the fourth quarter valued at about $33,000. Invesco Ltd. purchased a new position in shares of Enlivex Therapeutics in the 4th quarter worth about $43,000. XTX Topco Ltd increased its position in shares of Enlivex Therapeutics by 44.8% during the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Enlivex Therapeutics by 244.1% during the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after buying an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics during the 3rd quarter valued at about $57,000. 1.02% of the stock is owned by institutional investors.

Enlivex Therapeutics Stock Performance

Enlivex Therapeutics stock traded down $0.12 during mid-day trading on Thursday, hitting $1.72. 316,502 shares of the company traded hands, compared to its average volume of 86,830. Enlivex Therapeutics has a one year low of $1.70 and a one year high of $31.50. The stock has a market cap of $28.95 million, a price-to-earnings ratio of -0.21 and a beta of 1.60. The stock has a fifty day moving average price of $6.47 and a 200-day moving average price of $11.69.

Wall Street Analyst Weigh In

ENLV has been the topic of several research analyst reports. Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. Zacks Research upgraded Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $247.50.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.